EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Glycoscience in Advancing PD-1/PD-L1-Axis-Targeted Tumor Immunotherapy

Qiyue Sun, Senlian Hong iD

International Journal of Molecular Sciences · 31.01.2025 · 26 (3) · 1238

DOI: 10.3390/ijms26031238 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 31.01.2025. Verfasst von Qiyue Sun und 1 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center, Department of Chemical Biology, School of Pharmaceutical Sciences, Pek…. Hauptthemen laut MEDLINE: Neoplasms, Programmed Cell Death 1 Receptor, Immunotherapy, B7-H1 Antigen. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint blockade therapy, represented by anti-PD-1/PD-L1 monoclonal antibodies, has significantly changed the immunotherapy landscape. However, the treatment is still limited by unsatisfactory response rates, immune-related adverse effects, and drug resistance. Current studies have established that glycosylation, a common post-translational modification, is crucial in promoting cancer progression and immune invasion. Targeting aberrant glycosylation in cancers presents precision medicine regimens for monitoring cancer progression and developing personalized medicine. Notably, the immune checkpoints PD-1 and PD-L1 are highly glycosylated, which affects PD-1/PD-L1 interaction and the binding of anti-PD-1/PD-L1 monoclonal antibodies. Recent achievements in glycoscience to enhance patient outcomes, referred to as glycotherapy, have underscored their high potency in advancing PD-1/PD-L1 blockade therapies, i.e., glycoengineered antibodies with improved binding toward PD-1/PD-L1, pharmaceutic inhibitors for core fucosylation and sialylation, and synergistic treatment with the antibody–sialidase conjugate. This review briefly introduces the PD-1/PD-L1 axis and glycosylation and highlights the fundamental and applied advances in glycoscience that improve PD-1/PD-L1 immunoblockade therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsProgrammed Cell Death 1 ReceptorImmunotherapyB7-H1 AntigenImmune Checkpoint InhibitorsHumansGlycosylationAnimalsAntibodies, Monoclonal

Stichwörter der Autor:innen

PD-1/PD-L1 blockadesglycosylationimmunotherapy

Substanzen

Programmed Cell Death 1 ReceptorB7-H1 AntigenImmune Checkpoint InhibitorsAntibodies, MonoclonalCD274 protein, humanPDCD1 protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center, Department of Chemical Biology, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.

ORCID-Profile: Senlian Hong

Förderung

  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • Fundamental Research Funds for the Central Universities of China

Zitieren

APA

Sun, Q., & Hong, S. (2025). Glycoscience in Advancing PD-1/PD-L1-Axis-Targeted Tumor Immunotherapy. International Journal of Molecular Sciences, 26(3), 1238. https://doi.org/10.3390/ijms26031238

Vancouver

Sun Q, Hong S. Glycoscience in Advancing PD-1/PD-L1-Axis-Targeted Tumor Immunotherapy. International Journal of Molecular Sciences. 2025;26(3):1238. doi:10.3390/ijms26031238

BibTeX
@article{Sun2025,
  author = {Sun, Qiyue and Hong, Senlian},
  title = {Glycoscience in Advancing PD-1/PD-L1-Axis-Targeted Tumor Immunotherapy},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {3},
  pages = {1238},
  doi = {10.3390/ijms26031238}
}
Kostenlos starten →